A patient with HIV and tuberculosis with diminished clopidogrel response

International Journal of STD & AIDS
Nicole L Metzger, Kathryn M Momary

Abstract

Patients with HIV are at an increased risk for cardiovascular disease, both as a result of treatment with protease inhibitors and from the disease itself. The medication regimens of patients with HIV and cardiovascular comorbidities are complex and require careful assessment for potentially serious drug-drug interactions. We report a case of clopidogrel non-responsiveness in a patient with HIV, latent tuberculosis and cardiovascular disease with a history of myocardial infarction. To our knowledge, this is the first report of significant drug interactions between clopidogrel, isoniazid and ritonavir. This case underscores the importance of a detailed drug interaction screening in infectious disease patients taking complex medication regimens, including clopidogrel.

Citations

Apr 27, 2018·Clinical Pharmacology and Therapeutics·Matti K ItkonenJanne T Backman
Jun 4, 2015·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Andrew StolbachPaul Pham
Aug 5, 2020·The Journal of Antimicrobial Chemotherapy·Catherine HodgeSaye Khoo
Apr 18, 2018·British Journal of Clinical Pharmacology·Iria BravoJosé Moltó
Nov 24, 2020·European Heart Journal. Quality of Care & Clinical Outcomes·Monica M ParksPriscilla Y Hsue

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.